Financials data is unavailable for this security.
View more
Year on year Jubilant Pharmova Ltd grew revenues 6.70% from 62.82bn to 67.03bn while net income improved from a loss of 609.80m to a gain of 771.00m.
| Gross margin | 68.50% |
|---|---|
| Net profit margin | 8.51% |
| Operating margin | 12.51% |
| Return on assets | 5.05% |
|---|---|
| Return on equity | 10.45% |
| Return on investment | 6.01% |
More ▼
Cash flow in INRView more
In 2024, cash reserves at Jubilant Pharmova Ltd fell by 575.00m. However, the company earned 9.71bn from its operations for a Cash Flow Margin of 14.49%. In addition the company used 6.08bn on investing activities and also paid 4.33bn in financing cash flows.
| Cash flow per share | 60.96 |
|---|---|
| Price/Cash flow per share | 18.52 |
| Book value per share | 375.04 |
|---|---|
| Tangible book value per share | 150.71 |
More ▼
Balance sheet in INRView more
| Current ratio | 1.80 |
|---|---|
| Quick ratio | 1.20 |
| Total debt/total equity | 0.5185 |
|---|---|
| Total debt/total capital | 0.342 |
More ▼
Growth rates in INR
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 226.67%. Additionally when measured on a five year annualized basis, dividend per share growth is in-line with the industry average relative to its peers, while earnings per share growth is below the industry average.
| Div yield(5 year avg) | 1.17% |
|---|---|
| Div growth rate (5 year) | 2.13% |
| Payout ratio (TTM) | 13.42% |
| EPS growth(5 years) | -33.33 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 1,456.04 |
More ▼
